Literature DB >> 19208649

Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial.

Michał Tendera1, Wojciech Wojakowski, Witold Ruzyłło, Lidia Chojnowska, Cezary Kepka, Wiesława Tracz, Piotr Musiałek, Wiesława Piwowarska, Jadwiga Nessler, Paweł Buszman, Stefan Grajek, Piotr Breborowicz, Marcin Majka, Mariusz Z Ratajczak.   

Abstract

AIMS: Comparison of intracoronary infusion of bone marrow (BM)-derived unselected mononuclear cells (UNSEL) and selected CD34(+)CXCR4(+) cells (SEL) in patients with acute myocardial infarction (AMI) and reduced <40% left ventricular ejection fraction (LVEF). METHODS AND
RESULTS: Two hundred patients were randomized to intracoronary infusion of UNSEL (n = 80) or SEL (n = 80) BM cells or to the control (CTRL) group without BM cell treatment. Primary endpoint: change of LVEF and volumes measured by magnetic resonance imaging before and 6 months after the procedure. After 6 months, LVEF increased by 3% (P = 0.01) in patients treated with UNSEL, 3% in patients receiving SEL (P = 0.04) and remained unchanged in CTRL group (P = 0.73). There were no significant differences in absolute changes of LVEF between the groups. Absolute changes of left ventricular end-systolic volume and left ventricular end-diastolic volume were not significantly different in all groups. Significant increase of LVEF was observed only in patients treated with BM cells who had baseline LVEF < median (37%). Baseline LVEF < median and time from the onset of symptoms to primary percutaneous coronary intervention > or = median were predictors of LVEF improvement in patients receiving BM cells. There were no differences in major cardiovascular event (death, re-infarction, stroke, target vessel revascularization) between groups.
CONCLUSION: In patients with AMI and impaired LVEF, treatment with BM cells does not lead to a significant improvement of LVEF or volumes. There was however a trend in favour of cell therapy in patients with most severely impaired LVEF and longer delay between the symptoms and revascularization.

Entities:  

Mesh:

Year:  2009        PMID: 19208649     DOI: 10.1093/eurheartj/ehp073

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  142 in total

1.  Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy.

Authors:  David M Leistner; Ulrich Fischer-Rasokat; Jörg Honold; Florian H Seeger; Volker Schächinger; Ralf Lehmann; Hans Martin; Iris Burck; Carmen Urbich; Stefanie Dimmeler; Andreas M Zeiher; Birgit Assmus
Journal:  Clin Res Cardiol       Date:  2011-06-03       Impact factor: 5.460

Review 2.  CD34-positive stem cells: in the treatment of heart and vascular disease in human beings.

Authors:  Alexander R Mackie; Douglas W Losordo
Journal:  Tex Heart Inst J       Date:  2011

Review 3.  Intra-arterial delivery of cell therapies for stroke.

Authors:  Vivek Misra; Aditya Lal; Ramy El Khoury; Peng R Chen; Sean I Savitz
Journal:  Stem Cells Dev       Date:  2012-02-15       Impact factor: 3.272

Review 4.  Molecular mediators of mesenchymal stem cell biology.

Authors:  Maria P Alfaro; Sarika Saraswati; Pampee P Young
Journal:  Vitam Horm       Date:  2011       Impact factor: 3.421

Review 5.  Cell delivery routes for stem cell therapy to the heart: current and future approaches.

Authors:  Niall G Campbell; Ken Suzuki
Journal:  J Cardiovasc Transl Res       Date:  2012-05-31       Impact factor: 4.132

Review 6.  [Interventional, intramyocardial stem cell therapy in ischemic cardiomyopathy: update 2010].

Authors:  M W Bergmann; K Jaquet; C Schneider; K Krause; A Ujeyl; K-H Kuck
Journal:  Herz       Date:  2010-08       Impact factor: 1.443

7.  Current and future status of stem cell therapy in heart failure.

Authors:  David A D'Alessandro; Robert E Michler
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-12

Review 8.  Stem cells in the infarcted heart.

Authors:  Dinender K Singla
Journal:  J Cardiovasc Transl Res       Date:  2009-11-20       Impact factor: 4.132

9.  General overview of the Sixth International Symposium on Stem Cell Therapy and Cardiovascular Innovations.

Authors:  Ma Eugenia Vázquez-Alvarez; Ricardo Sanz-Ruiz; Enrique Gutiérrez; Adolfo Villa; Ma Eugenia Fernández; Sandra Vázquez; Ma José Lorenzo; Lucía Fernández; Isaac Pascual; Pedro L Sánchez; Francisco Fernández-Avilés
Journal:  J Cardiovasc Transl Res       Date:  2009-12-10       Impact factor: 4.132

10.  Bone marrow derived stem cells in regenerative medicine as advanced therapy medicinal products.

Authors:  Giuseppe Astori; Sabrina Soncin; Viviana Lo Cicero; Francesco Siclari; Daniel Sürder; Lucia Turchetto; Gianni Soldati; Tiziano Moccetti
Journal:  Am J Transl Res       Date:  2010-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.